Sectors & IndustriesHealthcareDrug Manufacturers - Specialty & Generic

Best Pharmaceutical Stocks to Buy Now (2025)

Top pharmaceutical stocks in 2025 ranked by overall Due Diligence Score. See the best pharmaceutical stocks to buy now, according to analyst forecasts for the drug manufacturers - specialty & generic industry.

According to Due Diligence Score, the 3 best pharma stocks to buy right now are:

Neurocrine Biosciences (NASDAQ:NBIX) is the top pharmaceutical stock with a Due Diligence Score of 75, which is 50 points higher than the pharmaceutical industry average of 25. It passed 25 out of 33 due diligence checks and has strong fundamentals. Neurocrine Biosciences has seen its stock lose -10.03% over the past year, overperforming other pharmaceutical stocks by 21 percentage points.

Neurocrine Biosciences has an average 1 year price target of $163.15, an upside of 33.06% from Neurocrine Biosciences's current stock price of $122.62.

Neurocrine Biosciences stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 13 analysts covering Neurocrine Biosciences, 61.54% have issued a Strong Buy rating, 23.08% have issued a Buy, 15.38% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Siga Technologies (NASDAQ:SIGA) is the second best pharmaceutical stock with a Due Diligence Score of 62, which is 37 points higher than the pharmaceutical industry average of 25. It passed 23 out of 38 due diligence checks and has strong fundamentals. Siga Technologies has seen its stock return 28.57% over the past year, overperforming other pharmaceutical stocks by 60 percentage points.

Collegium Pharmaceutical (NASDAQ:COLL) is the third best pharmaceutical stock with a Due Diligence Score of 51, which is 26 points higher than the pharmaceutical industry average of 25. It passed 17 out of 33 due diligence checks and has strong fundamentals. Collegium Pharmaceutical has seen its stock lose -7.2% over the past year, overperforming other pharmaceutical stocks by 24 percentage points.

Collegium Pharmaceutical has an average 1 year price target of $43.50, an upside of 41.14% from Collegium Pharmaceutical's current stock price of $30.82.

Collegium Pharmaceutical stock has a consensus Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Collegium Pharmaceutical, 25% have issued a Strong Buy rating, 50% have issued a Buy, 25% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 6 pharmaceutical stocks that have issued dividends in the past year, the 3 pharmaceutical stocks with the highest dividend yields are:

Siga Technologies (NASDAQ:SIGA) has an annual dividend yield of 10.26%, which is 7 percentage points higher than the pharmaceutical industry average of 3.04%.

Siga Technologies's dividend payout ratio of 50% indicates that its high dividend yield is sustainable for the long-term.

Perrigo Co (NYSE:PRGO) has an annual dividend yield of 3.37%, which is the same as the pharmaceutical industry average of 3.04%. Perrigo Co's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Perrigo Co's dividend has shown consistent growth over the last 10 years.

Perrigo Co's dividend payout ratio of -95.3% indicates that its dividend yield might not be sustainable for the long-term.

Phibro Animal Health (NASDAQ:PAHC) has an annual dividend yield of 2.03%, which is -1 percentage points lower than the pharmaceutical industry average of 3.04%. Phibro Animal Health's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Phibro Animal Health's dividend has shown consistent growth over the last 10 years.

Phibro Animal Health's dividend payout ratio of 100% indicates that its dividend yield might not be sustainable for the long-term.

Pharmaceutical stocks were down -3.51% in the last day, and down -1.08% over the last week. Canopy Growth was the among the top losers in the drug manufacturers - specialty & generic industry, dropping -27.34% yesterday.

Canopy Growth shares are trading lower following Q3 earnings.

Based on WallStreetZen's Valuation Score, the 3 most undervalued pharmaceutical stocks right now are:

Collegium Pharmaceutical (NASDAQ:COLL) is the most undervalued pharmaceutical stock based on WallStreetZen's Valuation Score. Collegium Pharmaceutical has a valuation score of 71, which is 58 points higher than the pharmaceutical industry average of 13. It passed 5 out of 7 valuation due diligence checks.

Collegium Pharmaceutical's stock has dropped -7.2% in the past year. It has overperformed other stocks in the pharmaceutical industry by 24 percentage points.

Siga Technologies (NASDAQ:SIGA) is the second most undervalued pharmaceutical stock based on WallStreetZen's Valuation Score. Siga Technologies has a valuation score of 57, which is 44 points higher than the pharmaceutical industry average of 13. It passed 4 out of 7 valuation due diligence checks.

Siga Technologies's stock has gained 28.57% in the past year. It has overperformed other stocks in the pharmaceutical industry by 60 percentage points.

Amphastar Pharmaceuticals (NASDAQ:AMPH) is the third most undervalued pharmaceutical stock based on WallStreetZen's Valuation Score. Amphastar Pharmaceuticals has a valuation score of 57, which is 44 points higher than the pharmaceutical industry average of 13. It passed 4 out of 7 valuation due diligence checks.

Amphastar Pharmaceuticals's stock has dropped -38.88% in the past year. It has underperformed other stocks in the pharmaceutical industry by -8 percentage points.